Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.

BACKGROUND Prostate-specific antigen (PSA) testing has increased in several countries. There is incomplete knowledge of PSA testing patterns. OBJECTIVE Determine the prevalence of PSA testing and explore patterns of PSA retesting in Stockholm County, Sweden. DESIGN, SETTING, AND PARTICIPANTS A population-based study was performed. Through registry linkages, we collected population information, data on PSA tests, pathology reports, and clinical information. The study population comprised males living in Stockholm County in 2011 (n=1034129), of which 229 872 had a PSA test during the period 2003-2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS We determined limited-duration-point prevalence of PSA testing and performed survival analysis on PSA retesting for men aged 40-89 yr. RESULTS AND LIMITATIONS The number of PSA tests increased from 54239 in 2003 to 124613 in 2011. During the 9-yr study period, 46%, 68%, and 77% of men without a prior prostate cancer (PCa) diagnosis and aged 50-59 yr, 60-69 yr, and 70-79 yr, respectively, had a PSA test. During 2010 and 2011, 25%, 40%, and 46% of men aged 50-59 yr, 60-69 yr, and 70-79 yr, respectively, had a PSA test. The prevalence of PSA testing increased from 2003 to 2011. The probability of retesting was PSA and age dependent, with a 26-mo cumulative incidence of 0.337 (95% confidence interval, 0.333-0.341) if the first PSA value was <1 ng/ml. The main limitations were (1) that PSA data prior to 2003 were not available and (2) that the study cohort was restricted to men who were alive in 2011. CONCLUSIONS Although screening for PCa is not recommended in Sweden, PSA testing in Stockholm County was high across ages ranging from 40 to 89 yr and increased during the period 2003-2011. The probability of PSA retesting was high, regardless of the original PSA level. These results contrast with current clinical recommendations and raise calls for a change, either through structured PCa testing or more detailed guidelines on PSA testing.

[1]  S. Bojesen,et al.  Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Supramaniam,et al.  Prostate cancer and prostate‐specific antigen testing in New South Wales , 2008, The Medical journal of Australia.

[3]  E. Feuer,et al.  Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey , 2007, Cancer.

[4]  L. Holmberg,et al.  The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.

[5]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[6]  Thomas Wiegel,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[7]  P. Carroll,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .

[8]  A. Ruffion,et al.  Consommation du dosage de l’antigène spécifique de la prostate (PSA) en France chez les hommes sans cancer de la prostate déclaré (2008-2010) , 2012 .

[9]  W. Catalona,et al.  Platinum Priority – Collaborative Review – Prostate Cancer Baseline Prostate-specific Antigen Testing at a Young Age Hemodilution and Psa Concentration among Men with Prostate Psa Values Using Sequence Variants Associated with Psa Levels. Sci Goteborg Randomised Population-based Prostate-cancer Scre , 2022 .

[10]  S. Duffy,et al.  Uptake of prostate‐specific antigen testing for early prostate cancer detection in Sweden , 2011, International journal of cancer.

[11]  Philip D. Harvey,et al.  A systematic review of the diagnostic accuracy of prostate specific antigen , 2009, BMC urology.

[12]  H. Comber,et al.  Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines , 2010, Irish journal of medical science.

[13]  A. Jha,et al.  Trends in prostate-specific antigen testing from 1995 through 2004. , 2007, Archives of internal medicine.

[14]  P. Scardino,et al.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.

[15]  S. Moss,et al.  Rates of prostate‐specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross‐sectional study , 2004, BJU international.

[16]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[17]  Hans Garmo,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.

[18]  J. Oesterling,et al.  Predictive properties of serum-prostate-specific antigen testing in a community-based setting. , 1996, Archives of internal medicine.

[19]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[20]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[21]  F. Hamdy,et al.  Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities , 2011, BJU international.

[22]  Y. Taylor,et al.  Trends in Prostate-Specific Antigen Test Use, 2000–2005 , 2011, Public health reports.

[23]  J. Oesterling,et al.  The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.

[24]  J. Anderson,et al.  Age-specific reference ranges for serum prostate-specific antigen. , 1995, Urology.

[25]  Jim C Hu,et al.  2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. , 2012, JAMA.

[26]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[27]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.